Allergy Therapeutics Plc (LON:AGY) is the topic of conversation with Dr Gary Waanders Director of Healthcare Research at Zeus Capital. Since Allergy Therapeutics announced today that it has obtained approval to begin a phase I clinical trial of its Acarovac MPL vaccine in Spain, Gary explains what the product designed to do, what CTA clearance means for the product’s development and on the basis of a fully approved vaccine the sort of sales he thinks might be possible.
Gary is an experienced healthcare analyst having worked in the City since early 2001. He joined Zeus in January 2014 and is responsible for research coverage of all our Life Sciences corporate clients which include companies active in biotechnology, specialty pharmaceuticals, medical technology and clinical research services. He has worked on numerous IPOs and M&A mandates in the UK and Europe and has previously worked at Nomura Code Securities and KBC Peel Hunt. Prior to becoming an analyst, he managed an R&D group at a Canadian biotech company and before that he was a post-doctoral fellow at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. His academic training includes an MBA from the University of Durham Business School and a PhD in Immunology from the Faculty of Medicine at Monash University (Australia) where he also obtained a BSc (Hons) in Immunology and Biochemistry.
Allergy Therapeutics plc is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.495 employees and is listed on the London Stock Exchange.